Teva Pharmaceutical Industries Stock Forecast for 2023 - 2025 - 2030

Updated on 04/22/2024

Stock Rating
12
Price Target
$16.00
Consensus
Outperform
Upside
24.42%
Analysts
9
Stock Rating
12
Upside
24.42%
Analysts
9
Price Target
$16.00

Teva Pharmaceutical Industries Stock Forecast and Price Target

The average target price set lately by nine experts for Teva Pharmaceutical Industries to reach by the end of the year is $16.00, which would imply a potential upside of approximately 24.42 percent from the previous closing price if it were to be achieved. This prediction is based on a high estimate of $19.00 and a low estimate of $11.00. If you're looking to buy Teva Pharmaceutical Industries stock, you may also want to check out its rivals.

$16.00

24.42% Upside

Outperform
Outperform

Teva Pharmaceutical Industries Fair Value Forecast for 2023 - 2025 - 2030

In the last four years, Teva Pharmaceutical Industries's Price has gone down from $9.33 to $0.00 – a 100.00% drop. In the next year, analysts expect Fair Value to reach $8.78 – an increase of 100.00%. For the next eight years, the forecast is for Fair Value to grow by 100.00%.

2024 Fair Value Forecast
$8.78
2025 Fair Value Forecast
$9.40
2026 Fair Value Forecast
$9.66
2027 Fair Value Forecast
$9.84
2028 Fair Value Forecast
$11.36
2029 Fair Value Forecast
$11.04
2030 Fair Value Forecast
$10.74
2030 Fair Value Forecast
$10.74
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
LLY Stock Forecast Eli Lilly and Outperform 16
$726.31 Buy/Sell $636.99 15.31%
JNJ Stock Forecast Johnson & Johnson Outperform 9
$147.91 Buy/Sell $174.55 14.93%
MRK Stock Forecast Merck Outperform 2
$125.78 Buy/Sell $130.51 10.91%
ABBV Stock Forecast AbbVie Outperform 9
$166.41 Buy/Sell $178.42 13.57%
AZN Stock Forecast AstraZeneca PLC Outperform 17
£109.46 Buy/Sell £165.99 47.83%

Teva Pharmaceutical Industries Revenue Forecast for 2023 - 2025 - 2030

In the last three years, Teva Pharmaceutical Industries's Revenue has gone down from $16.66B to $15.85B – a 4.88% drop. In the next year, 10 analysts estimate that Teva Pharmaceutical Industries's Revenue will decrease by 2.89%, reaching $15.39B. For the next eight years, the forecast is for Revenue to grow by 26.94%.

2024 Rev Forecast
$15.39B
2025 Rev Forecast
$15.69B
2026 Rev Forecast
$15.92B
2027 Rev Forecast
$16.13B
2028 Rev Forecast
$18.39B
2028 Rev Forecast
$18.39B
2029 Rev Forecast
$19.28B
2030 Rev Forecast
$20.12B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
ABT Stock Forecast Abbott Laboratories Outperform 9
$107.28 Buy/Sell $118.92 18.38%
AMGN Stock Forecast Amgen Outperform 4
$268.93 Buy/Sell $303.65 17.97%
BMY Stock Forecast Bristol-Myers Squibb Hold 2
$48.93 Buy/Sell $58.15 12.41%

Teva Pharmaceutical Industries Dividend per Share Forecast for 2023 - 2025 - 2030

2024 DPS Forecast
$0.00
2025 DPS Forecast
$0.00
2026 DPS Forecast
$0.00
2027 DPS Forecast
$0.00
2028 DPS Forecast
$0.00
2029 DPS Forecast
$0.00
2030 DPS Forecast
$0.00
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
GILD Stock Forecast Gilead Sciences Inc Outperform 11
$66.76 Buy/Sell $87.82 19.83%
GSK Stock Forecast GSK Outperform 12
£15.99 Buy/Sell £17.30 21.95%
MRK Stock Forecast Merck KGaA Outperform 18
146.00€ Buy/Sell 190.06€ 25.34%

Teva Pharmaceutical Industries Free Cash Flow Forecast for 2023 - 2025 - 2030

2024 FCF Forecast
$2.42B
2025 FCF Forecast
$2.07B
2026 FCF Forecast
$1.70B
2027 FCF Forecast
$2.08B
2028 FCF Forecast
$2.33B
2029 FCF Forecast
$2.45B
2030 FCF Forecast
$2.70B
2030 FCF Forecast
$2.70B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
MMM Stock Forecast 3M Hold 10
$92.27 Buy/Sell $109.39 8.38%
LONN Stock Forecast Lonza Group Buy 16
CHF502.80 Buy/Sell CHF516.89 16.35%
ALC Stock Forecast Alcon Outperform 8
CHF72.48 Buy/Sell CHF90.64 32.95%

Teva Pharmaceutical Industries EBITDA Forecast for 2023 - 2025 - 2030

In the last three years, Teva Pharmaceutical Industries's EBITDA has decreased by 6.05%, going from $4.61B to $4.33B. Next year, analysts are expecting EBITDA to reach $4.70B – an increase of 8.44%. Over the next eight years, the forecast is for EBITDA to grow by 35.15%.

2024 EBITDA Forecast
$4.70B
2025 EBITDA Forecast
$4.89B
2026 EBITDA Forecast
$5.02B
2027 EBITDA Forecast
$5.10B
2027 EBITDA Forecast
$5.10B
2028 EBITDA Forecast
$5.96B
2029 EBITDA Forecast
$5.85B
2030 EBITDA Forecast
$5.86B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
DSFIR Stock Forecast DSM-Firmenich Outperform 18
104.10€ Buy/Sell 114.60€ 15.27%
BAYN Stock Forecast Bayer Hold 5
26.33€ Buy/Sell 45.15€ 21.53%
GMAB Stock Forecast Genmab A/S Outperform 16
kr2.01k Buy/Sell kr2.71k 27.87%

Teva Pharmaceutical Industries EBIT Forecast for 2023 - 2025 - 2030

In the last three years, Teva Pharmaceutical Industries's EBIT has grown by 4.09%, rising from $3.06B to $3.18B. For next year, analysts predict EBIT of $4.19B, which would mean an increase of 31.65%. Over the next nine years, experts predict that Teva Pharmaceutical Industries's EBIT will grow at a rate of 17.30%.

2024 EBIT Forecast
$4.19B
2025 EBIT Forecast
$4.39B
2025 EBIT Forecast
$4.39B
2026 EBIT Forecast
$4.46B
2027 EBIT Forecast
$4.39B
2027 EBIT Forecast
$4.39B
2028 EBIT Forecast
$3.53B
2029 EBIT Forecast
$3.67B
2030 EBIT Forecast
$3.73B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
PHIA Stock Forecast Koninklijke Philips N.V. Hold 18
18.85€ Buy/Sell 19.42€ 3.45%
4503 Stock Forecast Astellas Pharma Outperform 18
¥1.48k Buy/Sell ¥2.64k 40.16%
FRE Stock Forecast Fresenius SE & Co. KGaA Outperform 18
26.90€ Buy/Sell 38.63€ 28.25%

Teva Pharmaceutical Industries EPS Price Prediction Forecast for 2023 - 2025 - 2030

In the last four years, Teva Pharmaceutical Industries's EPS has gone down from $2.57 to $0.00 – a 100.00% drop. In the next year, analysts expect EPS to reach $2.42 – an increase of 100.00%. For the next eight years, the forecast is for EPS to grow by 100.00%.

2024 EPS Forecast
$2.42
2025 EPS Forecast
$2.59
2026 EPS Forecast
$2.66
2027 EPS Forecast
$2.71
2028 EPS Forecast
$3.13
2029 EPS Forecast
$3.04
2030 EPS Forecast
$2.96
2030 EPS Forecast
$2.96
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
NBIX Stock Forecast Neurocrine Biosciences Outperform 16
$132.00 Buy/Sell $138.03 17.05%
CIPLA Stock Forecast Cipla Outperform 18
Rp1.35k Buy/Sell Rp1.43k 11.35%
500124 Stock Forecast Dr. Reddy's Laboratories Hold 18
Rp5.94k Buy/Sell Rp5.67k 1.81%